QR Code

Efficacy of osimertinib in patients with EGFR‐mutation positive non‐small cell lung cancer with malignant pleural effusion

Abstract Background As an epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI), osimertinib has emerged as a standard EGFR‐mutation positive treatment for non‐small cell lung cancer (NSCLC). However, the efficacy of osimertinib for malignant pleural effusion (MPE) remains understudi...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Wiley 2024-02-01
Rangatū:Thoracic Cancer
Ngā marau:
EGFR
malignant pleural effusion
non‐small cell lung cancer
osimertinib
Urunga tuihono:https://doi.org/10.1111/1759-7714.15210
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite